GMAB - Genmab - ADR
IEX Last Trade
27.81
0 0%
Share volume: 341,583
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$27.81
0.00
0.00%
Fundamental analysis
43%
Profitability
55%
Dept financing
2%
Liquidity
50%
Performance
40%
Performance
5 Days
1.68%
1 Month
-1.45%
3 Months
-0.68%
6 Months
0.47%
1 Year
-29.06%
2 Year
-21.16%
Key data
Stock price
$27.81
DAY RANGE
N/A - N/A
52 WEEK RANGE
$24.53 - $38.80
52 WEEK CHANGE
-$0.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Jan van de Winkel
Region: US
Website: http://www.genmab.com/
Employees: 781
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.genmab.com/
Employees: 781
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
Recent news